Production (Stage)
Citius Pharmaceuticals, Inc.
CTXR
$0.703
-$0.021-2.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -5.29% | -2.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.16% | -9.15% | |||
| Operating Income | -12.16% | 9.15% | |||
| Income Before Tax | -12.28% | 8.38% | |||
| Income Tax Expenses | 0.00% | 83.47% | |||
| Earnings from Continuing Operations | -11.97% | 7.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 15.98% | 78.75% | |||
| Net Income | -11.76% | 9.47% | |||
| EBIT | -12.16% | 9.15% | |||
| EBITDA | -12.16% | 9.15% | |||
| EPS Basic | 2.42% | 18.10% | |||
| Normalized Basic EPS | 2.26% | 15.23% | |||
| EPS Diluted | 2.42% | 23.42% | |||
| Normalized Diluted EPS | 2.26% | 15.23% | |||
| Average Basic Shares Outstanding | 14.53% | 3.57% | |||
| Average Diluted Shares Outstanding | 14.53% | 3.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||